RecruitingPhase 1NCT07444385

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Period Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Volunteers Under Fed Conditions


Sponsor

Addpharma Inc.

Enrollment

44 participants

Start Date

Feb 26, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects


Eligibility

Sex: MALEMin Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AD-116, AD-1161 for people with benign prostatic hyperplasia. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAD-116, AD-1161

Single-dose oral administration of AD-116 or AD-1161, according to randomized sequence.


Locations(1)

H PLUS YANGJI HOSPITAL, Seoul

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07444385


Related Trials